CircEZH2-encoded EZH2-92aa is overexpressed in clinical GBM tumours and decreases susceptibility to NK cell cytotoxicity by suppressing the expression of NKG2D ligands, suggesting that NK cell-based therapies can be combined with EZH2-92aa targeting strategies to improve clinical outcomes of this lethal tumour. This evidence concerns the gene EZH2 and glioblastoma.